NAD+ injection vs nasal spray: choosing your cellular-health protocol
Both deliver NAD+. They reach the cell differently, work at different intensities, and fit different patient goals. A practical decision framework for picking between them — or stacking them.
NAD+ (nicotinamide adenine dinucleotide) is the cellular cofactor at the center of mitochondrial energy production, DNA repair, and dozens of redox reactions that keep cells functioning. Levels decline with age, stress, and metabolic dysfunction — and supplementing NAD+ has become one of the most-prescribed longevity-leaning protocols in concierge medicine.
The clinical question isn't whether NAD+ supplementation works (the evidence base is strong). It's how to deliver it. Two formats dominate concierge practice: injectable and nasal spray. Here's how they differ, when each fits, and how they're often used together.
Why NAD+ at all?
NAD+ is consumed every time the cell does any of three things: extract energy from food via the electron transport chain, repair DNA damage, or run sirtuin-mediated longevity pathways. Cellular NAD+ levels fall by 50%+ between age 20 and age 60 in most tissues studied.
The clinical effects of supplemented NAD+ that show up in patient-reported outcomes:
- Mental clarity and cognitive sharpness, particularly in patients dealing with brain fog
- Energy stability without caffeine spikes
- Sleep depth and recovery from exertion
- Mitochondrial-supported endurance during sustained effort
Oral NAD+ doesn't work the way the marketing implies — the molecule is rapidly broken down in the gut into precursors before reaching the cell. That's why injectable and nasal-spray formats exist: they bypass first-pass metabolism.
NAD+ injection
Subcutaneous or intramuscular injection delivers NAD+ directly into systemic circulation. Bioavailability is high and predictable; serum levels rise quickly and stay elevated for 4–8 hours per dose.
Pros: Reliable bioavailability. Higher therapeutic doses possible (250–500mg per injection, sometimes higher in IV protocols). Stronger patient-reported response in the first 4–8 weeks. Most data and longest clinical history of this delivery format.
Cons: Subcutaneous injection (mild local stinging is common — NAD+ has a slight pH mismatch with subcutaneous tissue). Higher cost per dose. Requires comfort with self-injection. Loading-phase protocol typically runs 5–7 doses over 2 weeks, which is meaningful needle work.
Who fits: patients with significant cellular-energy issues, post-illness recovery, brain fog, or those committing to a serious longevity protocol who want the strongest available response. Patients who've already run protocols with consistent injection adherence.
NAD+ nasal spray
Intranasal delivery routes NAD+ across the nasal mucosa directly to the central nervous system via the olfactory pathway, partially bypassing systemic circulation. Bioavailability is lower than injection but the central-nervous-system delivery is arguably more efficient for cognitive applications.
Pros: No needles. Daily use is sustainable. Lower per-dose cost. Direct CNS targeting for cognitive use cases. Pairs well with periodic injection loading.
Cons: Lower systemic bioavailability — for patients who need whole-body response (energy, recovery, athletic performance), nasal-only may not be enough. Patient-reported response is more subtle and slower-onset than injection. Mild nasal irritation possible at higher concentrations.
Who fits: patients prioritizing cognitive support, mental clarity, or daily- maintenance use. Patients who can't commit to injection adherence. Patients in maintenance after an injection-based loading phase.
Side-by-side
- Bioavailability. Injection: high, systemic. Nasal: moderate, CNS-targeted.
- Onset. Injection: minutes to hours. Nasal: gradual over weeks.
- Patient experience. Injection: needle, stinging at site. Nasal: simple daily spray.
- Cost. Injection: higher per dose. Nasal: lower per dose, sustainable for daily use.
- Best for. Injection: energy, recovery, post-illness. Nasal: cognition, daily maintenance.
The loading + maintenance approach
Most patients in our practice run a hybrid protocol that uses both formats deliberately:
- Loading phase — 2–4 weeks of injectable NAD+ (250–500mg, 3–5 doses per week). Restores cellular NAD+ levels quickly and produces the strongest patient- reported response.
- Maintenance phase — daily nasal spray for 8–12 weeks afterward. Holds the gains without the burden of continued injection.
- Re-loading — quarterly or twice-yearly injection cycles to maintain levels long-term. The cellular reset effect of a fresh loading cycle is real; patient-reported response often returns or strengthens.
How Vektor structures NAD+ protocols
For new NAD+ patients, we usually start with a 2–3 week injection loading phase (under direct physician oversight given some patients tolerate the loading better than others), then transition to daily nasal spray for maintenance. We re-load quarterly or twice yearly depending on patient response and goal.
NAD+ is rarely a standalone protocol in our practice. It sits alongside hormone optimization, peptide work, or GLP-1 protocols where the cellular-energy boost compounds the response. For a patient on TRT, sermorelin, and a cleaned-up sleep routine, adding NAD+ is the difference between “significantly better” and “genuinely transformed.”
Founding 100 — now open
Lock $149/mo Concierge for life — limited to the first 100 members.
Vektor Health is a private, physician-led telehealth practice for hormone optimization, peptide therapy, and metabolic medicine. Anchored in the NJ/NY area; launching across all 50 states.
Reserve a founding spot